Bibliography for: "Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision"

"Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision". Business Wire. FindArticles.com. 09 Dec, 2009. http://findarticles.com/p/articles/mi_m0EIN/is_2007_June_2/ai_n19188484/

Business Wire

View more issues:

Articles in June 2, 2007 issue of Business Wire

• Redding Man Looks to Care for Wife after Big Win on `The Big Spin®' Show
• Results of VEGF Trap Highlighted at ASCO 2007 Annual Meeting
• San Diego Local Receives Toastmasters Honor
• ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
• Data from ArQule's Phase 1 Trial with c-Met Inhibitor, ARQ 197, Demonstrate Safety and Expanded Anti-Cancer Activity
• Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
• Investing Systems Stock Picking Software Delivers High Powered Gains for Short-Term Traders
• Reed's Inc Announces $4.671 Million Capital Raise
• Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
• Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
• ZIO-101 Early Interim Multiple Myeloma Phase I/II Data Presented at ASCO
• Clark Nuber Team Member Completes PHR Designation
• Synplicity Announces Agreement to Acquire HARDI Electronics AB
• Kamen Joins ALIC Board of Governors
• Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision
• Radio Address by the President to the Nation
• Amata Inc. to Provide State-of-the-Art Security System for Pacific Texas Pipeline & Transportation Company
• Green Energy Conference in Pasadena to Introduce Significant New Technologies
• INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
• Emvelco Generates Operating Loss; Earns Net Income Based on Discontinued Operations
• FPL Ready to Respond to Barry and Urges Customers to Be Safe
• Cyclacel Reports Phase I Sapacitabine Data in Patients with Advanced Leukemias and Myelodysplastic Syndromes at 2007 ASCO Annual Meeting
• ZIO-101 Phase I Advanced Solid Tumor Data Presented at ASCO
• New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
• Herbalife Ltd. to Present at Morgan Stanley Small Cap Executive Conference
• BizBash Announces 2007 Event Style Award Los Angeles Finalists
• Virgin Mobile Chooses InfoSpace for World's Most Comprehensive Mobile Search
• Cirque du Soleil's Guy Laliberte named Ernst & Young 2007 World Entrepreneur Of The Year